Achieve Life Sciences, Inc. is a specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's lead product candidate is cytisinicline, a highly selective nicotinic acetylcholine receptor partial agonist that aims to reduce nicotine cravings and withdrawal symptoms. Achieve has completed Phase 3 clinical trials for cytisinicline in smoking cessation and has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration. Additionally, the company is advancing clinical programs to evaluate cytisinicline as a treatment for e-cigarette or vaping cessation. Achieve operates primarily in the United States and partners with third-party manufacturers, such as Adare Pharma Solutions, to advance its pipeline toward commercialization.
